Susquehanna International Group
ARQT icon

Susquehanna International Group’s Arcutis Biotherapeutics ARQT Stock Holding History

Susquehanna International Group’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.41M Sell
144,700
-127,700
-47% -$3.26M ﹤0.01% 5009
2025
Q4 		$7.91M Buy
272,400
+139,200
+105% +$3.56M ﹤0.01% 3352
2025
Q3 		$2.51M Buy
133,200
+38,400
+41% +$606K ﹤0.01% 5310
2025
Q2 		$1.33M Sell
94,800
-197,300
-68% -$2.77M ﹤0.01% 6727
2025
Q1 		$4.57M Buy
292,100
+50,600
+21% +$713K ﹤0.01% 3819
2024
Q4 		$3.36M Buy
241,500
+61,500
+34% +$674K ﹤0.01% 4256
2024
Q3 		$1.67M Buy
180,000
+17,700
+11% +$175K ﹤0.01% 5656
2024
Q2 		$1.51M Sell
162,300
-250,400
-61% -$2.26M ﹤0.01% 5658
2024
Q1 		$4.09M Buy
412,700
+398,400
+2,786% +$2.97M ﹤0.01% 3976
2023
Q4 		$46.2K Buy
+14,300
New +$38.9K ﹤0.01% 11740
2023
Q3 		– Sell
-115,300
Closed -$1.1M – 11968
2023
Q2 		$1.1M Buy
115,300
+87,900
+321% +$976K ﹤0.01% 6459
2023
Q1 		$301K Sell
27,400
-145,600
-84% -$2.11M ﹤0.01% 9707
2022
Q4 		$2.56M Buy
173,000
+130,800
+310% +$2.29M ﹤0.01% 4274
2022
Q3 		$806K Buy
42,200
+15,200
+56% +$344K ﹤0.01% 7195
2022
Q2 		$575K Buy
27,000
+8,000
+42% +$164K ﹤0.01% 7907
2022
Q1 		$366K Sell
19,000
-9,800
-34% -$166K ﹤0.01% 9755
2021
Q4 		$597K Buy
28,800
+18,100
+169% +$360K ﹤0.01% 8698
2021
Q3 		$256K Sell
10,700
-77,900
-88% -$1.78M ﹤0.01% 10958
2021
Q2 		$2.42M Buy
+88,600
New +$2.5M ﹤0.01% 5487

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group's ARQT Position: Q1 2026 in Review

Susquehanna International Group increased its Arcutis Biotherapeutics (ARQT) stake by 1,165% in Q1 2026, buying an estimated $2.64M and bringing the position to 112,179 shares worth $2.64M. The position accounts for ﹤0.01% of the portfolio, ranked #5541.

Susquehanna International Group first reported a position in ARQT in Q2 2020 and has held it in 24 quarters since. The position peaked at $3.66M in Q2 2025. 270 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • Susquehanna International Group held 112,179 shares of Arcutis Biotherapeutics worth $2.64M as of Q1 2026.
  • Susquehanna International Group bought 103,312 Arcutis Biotherapeutics shares in Q1 2026, an estimated $2.64M.
  • Arcutis Biotherapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #5541 holding.
  • Susquehanna International Group first reported a position in Arcutis Biotherapeutics in Q2 2020 and has held it in 24 quarters since.
  • Susquehanna International Group's Arcutis Biotherapeutics position peaked at $3.66M in Q2 2025.
  • 270 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.